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older than those without (37.5 vs. 34.5, p = 0.0017). The prevalence rate among all 
patients were 7.6% for diabetes, 13.3% for hypertension, 23.4% for hyperlipidemia, 
as compared to 3.4%, 8.5% and 6.8% in patients without HAART. There were sta-
tistically significant differences for diabetes (p = 0.0294) and hyperlipidemia (p < 
0.0001). The difference for hypertension is boradline statistically significant (p = 
0.0601). The mean expenditure per patient per year of dyslipidemia drugs, hypo-
glycemic drug, antihypertensive drug, and sedative hypnotic drug were not statisti-
cally significant. CONCLUSIONS: Per previous literature reviews, the prevalence of 
diabetes, hypertension, hyperlipidemia for HIV-infected patients with HAART was 
confirmed and increasing year by year using the real world data in Taiwan. Good 
control of metabolic co-morbidities to reduce the risk of morbidity and mortality 
is highly recommended.
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OBJECTIVES: E. coli is the most frequently encountered pathogen in clinical set up 
causing devastating infections irrespective of age and gender resulting in signifi-
cant morbidity and mortality. E. coli isolates have been found resistant to variety 
of antibiotics commonly used in empirical therapy at hospitals and clinics. CTX-M, 
TEM and SHV type extended spectrum beta-lactamases are mainly responsible 
for this resistance. The aim of this study was to investigate the prevalence of CTX-
M, TEM and SHV beta-lactamases in clinical isolates of E. coli and to assess the 
resulted economic burden on the poor population. METHODS: E. coliisolates were 
collected from a tertiary care hospital between 2012 and 2013, and tested against 
several classes of antibiotics on Kirby- Bauer disk diffusion methods to check their 
multidrug resistance phenotype. Presence and identification of CTX-M, SHV and 
TEM beta-lactamases were confirmed on PCR. RESULTS: Overall resistance pat-
tern to the tested antibiotics was amoxicillin(80%), cefazolin(74%), cefotaxime(63%), 
ceftazidime(58%), gentamycin(58%), ciprofloxacin(89%), levofloxacin(51%), chloram-
phenicol(38%), erythromycin(83%), amoxicillin/clavulanic acid(82%) and trimetho-
prim/sulfamethoxazole(91%). The prevalence of different beta-lactamase types in E. 
coliisolates was CTX-M(72 %), TEM(67%) and SHV(53%). CONCLUSIONS: CTX-M, TEM 
and SHV beta-lactamases are responsible for such overwhelming resistance in these 
isolates. These enzymes are present on mobile genetic elements such as plasmids 
which are readily exchanged between diverse bacterial communities and leading 
this alarming resistance to epidemic level. More than 50% of population live below 
the poverty line in Pakistan and cannot afford or have excess to expensive treat-
ments, such resistance is challenging the very health care system of the country. 
Both rate of infections and resistance to antimicrobials is on the rise and is sped 
up by the unregulated sub-standard health practice in Pakistan. The current health 
and economic losses are incalculable but the more devastating consequences to the 
humanity and economy are not too far from reality.
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OBJECTIVES: H1N1 influenza infection associated with higher morbidity and mor-
tality because of associated severe complications like acute respiratory distress 
syndrome (ARDS) and multiple organs dysfunction syndrome. We conducted a ret-
rospective study to evaluate the clinical characteristics, different complication and 
management strategies adopted to treat H1N1 patients in a tertiary care centre. To 
study the clinical features, complication, different risk factors affecting the outcome 
along with different management strategies used in the patients with confirmed 
H1N1influenza infection. METHODS: The medical records of 141 patients were ana-
lyzed retrospectively who were admitted to KMC Hospital, Manipal, from June 2012 
through May 2014. RESULTS: Among the study population 51.1% were female with 
mean age of 32.54 years. Among 55.3% patients admitted without any significant 
medical history and 44.7% patients had major problems like diabetes mellitus, res-
piratory tract infections and bronchial asthma. Fever with headache was observed 
in 92.9% followed by cough (78.7%) and breathlessness (54.6%). According to severity 
of disease 53.2% patients were put on mechanical ventilation. All the patients were 
started with oseltemivir for influenza management. The co-infections were treated 
by beta-lactams (60.28%) and macrolides (41.11%). Diuretics were given in 32.46%, 
anti-anxiety in 31.90% patients and antipyretics, bronchodilators and corticoster-
oids as supportive care in all patients. Mean of hospitalization period was 8.5 days. 
During the hospitalization the patients developed different complications like res-
piratory tract infections (31.20%), ARDS (17.7%) and sepsis (14.4%). The mortality rate 
of the study population was found to be 29.1 %. CONCLUSIONS: We observed that 
outcome was associated with low oxygen saturation during admission, metabolic 
acidosis, abnormal chest x-rays, use of diuretics, corticosteroids and anti-anxiety 
drugs. We also found that the complications like ARDS, sepsis and respiratory tract 
infections also influence the mortality rate.
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OBJECTIVES: This study assessed length of stay (LOS), inpatient costs and mortal-
ity among hospitalized patients with cSSSI treated with ceftaroline compared with 
illness (RIH rate: 7.03%) of which 196 tested RSV-positive (RSVH rate: 1.76%). All RIHs 
were not or probably not related to palivizumab. 62 single or multiple SAEs were 
documented in 52 infants. Fourteen events in 6 patients out of 62 SAEs were hyper-
sensitivity reactions (moderate: 11; mild: 3). These were deemed possibly (n= 10) or 
probably (n= 4) related to palivizumab (rate: 0.00028 events per patient-month). The 
remaining 48 SAEs in 46 patients were categorized as not related (n= 39), probably 
not related (n= 5), and unclassifiable (n= 4). CONCLUSIONS: Using an active surveil-
lance system, a very small proportion of infants in the CARESS registry experienced 
SAEs that had a clear relationship with palivizumab and these events appear to 
be idiosyncratic. In routine practice, palivizumab appears to be a safe and well-
tolerated antibody for RSV infection prophylaxis in high-risk children.
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OBJECTIVES: While infectious disease societies recommend weight-based loading 
doses of 25-30 mg/kg in critically ill patients, published meta-analyses describe 
increased vancomycin related nephrotoxicity at these doses. Our objective was to 
assess incidence of nephrotoxicity with vancomycin in emergency department (ED) 
sepsis patients when compliant with these recommendations. METHODS: This was 
a retrospective cohort study performed in three EDs. An electronic health record 
(EHR)-based clinical decision support tool provided guidance at the point of order for 
IV vancomycin compliant with recommendations. Inclusion criteria: age ≥ 18 years, 
IV vancomycin order, and hospital admission. Exclusion criteria: no documented 
weight, hemodialysis-dependent, or < 2 creatinine (Cr) values. The primary outcome 
was incidence of nephrotoxicity within 5 days defined as at least 2 serial Cr higher 
than the initial measurement by at least 0.5 mg/dL or 50% increase. The secondary 
outcome was acute kidney injury (AKI) within 5 days, defined as any single increase 
in Cr by 0.5mg/dL or 50%. Analyses compared the incidence of nephrotoxicity and 
AKI between patients who received high dose (> 20 mg/kg) versus low dose (≤ 20 mg/
kg). Parametric data were compared using the t-test and categorical data with chi-
squared tests. RESULTS: An EHR-based query identified 2131 consecutive patients 
prescribed IV vancomycin over 6 months. Of these, 1330 patients met study criteria 
for the primary outcome and 1631 patients met criteria for the secondary outcome. 
Nephrotoxicity occurred in 8% of patients. High dose vancomcyin was associated 
with a lower rate of nephrotoxicity (6% vs 11%, p< 0.05) and a lower rate of AKI (8% 
vs 13%, p< 0.05). CONCLUSIONS: Initial dosing of vancomycin > 20 mg/kg according 
to guidelines was associated with a decreased rate of nephrotoxicity compared with 
low doses. Future analyses should distinguish between the occurrence of nephro-
toxicity due to disease progression in severe sepsis versus vancomycin exposure.
PIN7
safety ProfIle of fluoroquINoloNes: aNalysIs of adverse 
drug reactIoNs IN relatIoN to coNsumPtIoN data usINg 
PharmacovIgIlaNce database IN hebeI, chINa
Shi L.W.1, Han S.1, Zhao Y.L.2, Guan X.D.1
1International Research Center of Medical Administration, Peking University, Beijing, China, 
2School of Pharmaceutical Sciences, Peking University, Beijing, China
OBJECTIVES: The aim of this study was to reassess the safety profile of fluoroqui-
nolones using the database of adverse drug reactions (ADR) Spontaneous report 
system and the purchases data of fluoroquinolones. METHODS: All ADRs reported 
related to fluoroquinolones were retrieved from Center for Drug Monitoring and 
Evaluation (CDME) of Hebei. Reports were classified by System Organ Classes with 
MedDRAÂ®. Consumption data (numbers of defined daily dose [DDDs]) were used 
as denominators.Reporting rate and types of ADRs between different drugs were 
checked with Pearson’s chi-squared test, and a p-value of < 0.05 was considered 
statistically significant. RESULTS: Fluoroquinolones common ADRs related to skin 
and subcutaneous tissue, gastrointestinal, general disorders and administration site 
conditions. No delayed ADR or death caused by ADR was reported. Ofloxacin, levo-
floxacin and ciprofloxacin showed the lowest reporting rate adjusted by consump-
tion data. CONCLUSIONS: These data suggest that different fluoroquinolones were 
characterized by different rates and types of ADRs. In current application of fluoro-
quinolones, clinicians did not pay sufficient attention to delayed-ADRs and ADRs 
resulting in glucose metabolism disorder, which might lead to more safety problems.
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OBJECTIVES: Highly active antiretroviral therapy (HAART) was available for HIV-
infected patients in Taiwan since 1997. HAART can effectively reduce mortality 
and morbidity, but it may also increase the risk and related drug costs of metabolic 
co-morbidities for HIV-infected patients. The aim of this research was to investi-
gate the prevalence and treatment costs of metabolic co-morbidities such as dia-
betes, hypertension, and hyperlipidemia between HAART treated and not treated 
patients. METHODS: We conducted a population-based study using 1M sampling 
version of the National Health Insurance Research Database (NHIRD) from Taiwan 
between 2010 and 2012. We extracted HIV-infected patients from both outpatient 
and inpatient with primary or secondary diagnosis of HIV (ICD codes 042-044). 
Treatments such as HAART and other related information were extracted. The 
prevalence and related drug costs of metabolic co-morbidities was estimated and 
comparison were made using SAS version 9.3. RESULTS: In the sampling database, 
there were 488 and 235 HIV-infected patients with and without HAART treatments. 
They were mainly male (94.6% vs. 90.2%, p = 0.0255), HAART treated patients were 
